A078160 Stock Overview
MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||₩21,350.00|
|52 Week High||₩33,600.00|
|52 Week Low||₩16,750.00|
|1 Month Change||-15.95%|
|3 Month Change||19.27%|
|1 Year Change||-33.28%|
|3 Year Change||-35.89%|
|5 Year Change||-34.61%|
|Change since IPO||3.14%|
Recent News & Updates
Is MEDIPOST (KOSDAQ:078160) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
MEDIPOST's (KOSDAQ:078160) Stock Price Has Reduced 32% In The Past Three Years
MEDIPOST Co., Ltd. ( KOSDAQ:078160 ) shareholders should be happy to see the share price up 29% in the last quarter...
Is MEDIPOST (KOSDAQ:078160) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
|A078160||KR Healthcare||KR Market|
Return vs Industry: A078160 exceeded the KR Healthcare industry which returned -38.5% over the past year.
Return vs Market: A078160 underperformed the KR Market which returned -14.3% over the past year.
|A078160 Average Weekly Movement||7.6%|
|Healthcare Industry Average Movement||5.7%|
|Market Average Movement||5.5%|
|10% most volatile stocks in KR Market||10.4%|
|10% least volatile stocks in KR Market||3.1%|
Stable Share Price: A078160 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: A078160's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis.
MEDIPOST Fundamentals Summary
|A078160 fundamental statistics|
Is A078160 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A078160 income statement (TTM)|
|Cost of Revenue||₩22.99b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-42.32|
|Net Profit Margin||-1.24%|
How did A078160 perform over the long term?See historical performance and comparison
Is MEDIPOST undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate A078160's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A078160's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: A078160 is unprofitable, so we can't compare its PE Ratio to the Asian Healthcare industry average.
PE vs Market: A078160 is unprofitable, so we can't compare its PE Ratio to the KR market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A078160's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A078160's PB Ratio (2.2x) is in line with the KR Healthcare industry average.
How is MEDIPOST forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MEDIPOST has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has MEDIPOST performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A078160 is currently unprofitable.
Growing Profit Margin: A078160 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: A078160 is unprofitable, and losses have increased over the past 5 years at a rate of 3.8% per year.
Accelerating Growth: Unable to compare A078160's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A078160 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (33.4%).
Return on Equity
High ROE: A078160 has a negative Return on Equity (-0.6%), as it is currently unprofitable.
How is MEDIPOST's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: A078160's short term assets (₩81.1B) exceed its short term liabilities (₩41.4B).
Long Term Liabilities: A078160's short term assets (₩81.1B) exceed its long term liabilities (₩50.5B).
Debt to Equity History and Analysis
Debt Level: A078160 has more cash than its total debt.
Reducing Debt: A078160's debt to equity ratio has increased from 15.4% to 17.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A078160 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A078160 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 29.4% each year
What is MEDIPOST current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A078160's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A078160's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A078160's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A078160's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A078160 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Yoon Yang (57 yo)
Dr. Yoon Sun Yang serves as Chief Executive Officer and President of Medipost Co. Ltd. Dr. Yang served as Chief Director of Medipost and President of Medipost Co. Ltd. He is a Professor in Samsung Medical...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
MEDIPOST Co., Ltd.'s employee growth, exchange listings and data sources
- Name: MEDIPOST Co., Ltd.
- Ticker: A078160
- Exchange: KOSDAQ
- Founded: 2000
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: ₩344.700b
- Shares outstanding: 16.15m
- Website: https://www.medi-post.co.kr
Number of Employees
- MEDIPOST Co., Ltd.
- 21, Daewangpangyo-ro
- 644 beon-gil
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/12 00:00|
|End of Day Share Price||2022/05/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.